Clinical Trials News


Pancreatic Ductal Adenocarcinoma (PDA) Clinical Phase 1a/1b Trial


Adelaide Cancer Centre and Sun BioPharma,Inc. and it’s wholly owned subsidiary Sun BioPharma Australia Pty Ltd announced that on 4th June 2018 the first patient from Adelaide Cancer Centre was enrolled in a Phase 1a/1b study of Sun BioPharma’s drug, SBP-101, in combination with gemcitabine and nab-paclitaxel for front-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA).


A/Prof Dusan Kotasek, a co-founder of the Adelaide Cancer Centre and the Principle Investigator for this study commented, “Pancreatic cancer is a challenging disease with few significant options available with a meaningful impact on response rates and progression free survival. We are excited to participate in the clinical study, and to continue our evaluation of SBP-101 as front-line combination treatment for previously untreated patients with metastatic PDA.” Read More

Clinical Trials


Ashford Cancer Centre Research (ACCR) commenced clinical research trial studies in January 1998. Since that time it has now grown to become a major clinical and research trial facility centre. ACCR is committed to linking patient care with cancer trial research. Our dedicated clinical team of oncologists/haematologists and research trial coordinators manage the research process with patients in mind, across all tumour types.


Clinical trials are research studies that test new medical treatments that are not yet available to the general public, either as “stand alone” new treatments or new drugs which can be added to current treatment to improve disease outcomes. Clinical trials also gather information about how effective a new treatment is for humans and forms an important part of Adelaide Cancer Centre’s role as a research-based private oncology practice. There are more than 25-30 clinical trials active in many different cancers at ACCR at any one given time. ACCR clinical trials team work in close collaboration with your oncologist/haematologist, patients, research laboratories and Sponsor companies.


Our research complies with the following Australian and International codes:

  • NHMRC* National Statement on Ethical Conduct in Human Research (2007)
  • WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects
  • International Conference on Harmonisation-Good Clinical Practice (ICH-GCP E6)


Our aim at ACCR is to improve treatment and care and experience positive outcomes for cancer patients. Dedicated research is the key to better treatments, care and potential cures for cancer.


Whilst many of the clinical trials we participate in are sponsored by pharmaceutical companies, Ashford Cancer Centre Research belongs to several national and international bodies involved in clinical trial research.


These include;

  • ANZ Breast Cancer Trials Group (ANZBCTG)
  • Australian Gastro-Intestinal Trials Group (AGastrointestinalG)
  • ANZ Gynaecology/Oncology Group (ANZGOG)
  • European Organisation for Research & Treatment of Cancer (EORTC)
  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)


We are able to offer trials for a wide variety of different cancers. Your treating medical oncologist/haematologist will discuss any relevant trials with you if they believe you may be eligible.


All of our ACC oncologist/haematologist team also treat patients with conventional cancer management programs, so they are well placed to contest conventional thinking practices in the search for safer, gentler and longer term effective cancer treatments.


* National Health and Medical Research Council